Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Work In Process (2016 - 2026)

Amphastar Pharmaceuticals has reported Work In Process over the past 11 years, most recently at $40.4 million for Q4 2025.

  • For Q4 2025, Work In Process rose 23.27% year-over-year to $40.4 million; the TTM value through Dec 2025 reached $40.4 million, up 23.27%, while the annual FY2025 figure was $40.4 million, 23.27% up from the prior year.
  • Work In Process for Q4 2025 was $40.4 million at Amphastar Pharmaceuticals, down from $42.5 million in the prior quarter.
  • Over five years, Work In Process peaked at $43.8 million in Q1 2025 and troughed at $28.3 million in Q3 2023.
  • A 5-year average of $36.5 million and a median of $36.6 million in 2022 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: dropped 26.63% in 2023 and later skyrocketed 31.34% in 2025.
  • Year by year, Work In Process stood at $33.3 million in 2021, then grew by 11.39% to $37.1 million in 2022, then dropped by 16.9% to $30.8 million in 2023, then increased by 6.44% to $32.8 million in 2024, then increased by 23.27% to $40.4 million in 2025.
  • Business Quant data shows Work In Process for AMPH at $40.4 million in Q4 2025, $42.5 million in Q3 2025, and $43.6 million in Q2 2025.